Halozyme Therapeutic (HALO) Stock Price, Quote & News

Company Profile

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subc...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 794 8889

Fax: 858 704 8311

Website: halozyme.com

Address:

12390 El Camino Real, San Diego, United States

Sean29md Oct. 24 at 5:16 PM

$HALO Clearly, it was not the concern over earnings growth in 2030’s alone that’s been plaguing Halozyme with ridiculously low PE and PEG ratios. Investors reactions to both Evotec and Elektrofi M&A news show that there are significant other factors. Although Elektrofi is a far better fit for Halozyme and should at least partially address the earnings growth in 2030’s, the market reaction has been far more negative than a typical reaction to M&A news for the acquiring company. Yes the share price has gone up over the past several years (outperforming S&P and Nasdaq) but Halo’s EPS has far outgrown the share price so much so that Halozyme is not only far below its peers PE ratios, it also hovering near its own historical PE’s all time lows. The main reason behind this massive undervaluation is lack of storytelling. Strong CEO and C-suties tell a compelling story that attracts new investors. https://www.weforum.org/stories/2025/01/storytelling-key-to-success-in-the-disruption-era/

1 · Reply

ZacksResearch Oct. 23 at 4:06 PM

$HALO raises its 2025 outlook — but can partner royalties really power the next leg of growth? Revenue guidance is climbing on strong royalty momentum from Darzalex SC, Phesgo, and Vyvgart Hytrulo — yet dependence on partners still looms large. Full breakdown on what this means for Halozyme’s growth story 👉 https://www.zacks.com/stock/news/2775263/will-higher-royalties-from-partners-fuel-halos-growth-in-h2-2025?cid=sm-stocktwits-2-2775263-teaser-17308&ADID=SYND_STOCKTWITS_TWEET_2_2775263_TEASER_17308

0 · Reply

ZacksResearch Oct. 23 at 3:06 PM

$HALO's 37.6% rally YTD — examining its current valuation at this premium. 🚀 🔍 Revenue growth fueled by strong royalties from J&J's Darzalex SC, Roche's Phesgo, and argenx’s Vyvgart Hytrulo. 📈 EPS estimates for 2025 & 2026 are on the rise, but the stock trades at a pricey P/S ratio of 6.93 vs. the industry's 2.28. Discover if HALO's growth justifies its valuation here 👉 https://www.zacks.com/stock/news/2775263/will-higher-royalties-from-partners-fuel-halos-growth-in-h2-2025?cid=sm-stocktwits-2-2775263-body-17294&ADID=SYND_STOCKTWITS_TWEET_2_2775263_BODY_17294

0 · Reply

Sean29md Oct. 22 at 3:08 PM

$HALO markets will sniff out the new Enhanze deal (likely with Gilead). Don’t be surprised if halo share prices rise ahead of the official news. If it is indeed Gilead (based on the patent the two companies filed jointly), expect a minimum of 20-30% gains.

0 · Reply

Sean29md Oct. 21 at 4:23 PM

$HALO $GILD Halozyme's earnings release was supposed to be on 10/28. Now it's been moved back to 11/3 which is after Golead's 10/30 earnings call. Coincidence? The linked (see below) patent (WO2025188901) appears to describe the use of Halozyme's Enhanze drug delivery technology in combination with Trodelvy, which is a breast cancer therapy developed by Gilead[1]. The fact that Halozyme is filing intellectual property specifically covering the pairing of its Enhanze platform with a Gilead molecule strongly suggests ongoing technical collaboration, and is often a precursor to a formal commercial partnership or licensing agreement. The patent in question is a strong signal that Halozyme and Gilead are either in late-stage partnership discussions or at the threshold of a formal deal announcement covering Enhanze-enabled subcutaneous Trodelvy delivery. patentscope.wipo.int/search/en/deta…

0 · Reply

JarvisFlow Oct. 20 at 3:35 PM

Morgan Stanley has updated their rating for Halozyme Therapeutics ( $HALO ) to Overweight with a price target of 79.

1 · Reply

Sean29md Oct. 20 at 3:23 PM

$HALO Many thanks to Morgan Stanley for the opportunity to load up more one week ahead of earnings.

1 · Reply

Sean29md Oct. 20 at 2:33 PM

$HALO Many thanks to Morgan Stanley for the opportunity to load up more one week ahead of earnings.

0 · Reply

NoobyDoo Oct. 17 at 4:32 PM

$HALO Something big this way comes…Gilead partnership announcement soon? 🤔 I like our chances $HALO

1 · Reply

MoneyGroupLLC Oct. 17 at 3:39 PM

Enter: $HALO NOV 21 2025 $70 CALLS Buy in Price: $2.50 - $2.65 Take Profit: $3.55 Stop Bleeding: $2.20 ROI Potential: 42% Exit Within: 3 Weeks https://moneygroup.us/alerts

0 · Reply

Halozyme Just Bought Its Next Decade Of Growth

Oct 21, 2025, 8:30 AM EDT - 4 days ago

Halozyme to Report Third Quarter 2025 Financial and Operating Results

Oct 10, 2025, 8:35 AM EDT - 15 days ago

Strong And Rising: Halozyme Therapeutics Stock May Have More Upside

Oct 1, 2025, 3:22 PM EDT - 24 days ago

Halozyme Therapeutics, Inc. (HALO) M&A Call Transcript

Oct 1, 2025, 7:16 AM EDT - 24 days ago

Halozyme to buy Elektrofi for $750 million to expand drug delivery lineup

Oct 1, 2025, 7:00 AM EDT - 24 days ago

Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s

Sep 8, 2025, 10:29 AM EDT - 6 weeks ago

Halozyme Therapeutics, Inc. (HALO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 4, 2025, 5:34 PM EDT - 7 weeks ago

Halozyme Therapeutics, Inc. (HALO) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Prepared Remarks Transcript

Aug 29, 2025, 2:01 PM EDT - 2 months ago

Identify Superstar Stocks Like Halozyme with Money Flows

Aug 28, 2025, 8:30 AM EDT - 2 months ago

Halozyme to Participate at Upcoming Investor Conferences

Aug 6, 2025, 5:45 AM EDT - 2 months ago

Halozyme Therapeutics, Inc. (HALO) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 4:01 PM EDT - 2 months ago

HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG SECOND QUARTER 2025 RESULTS

Jul 23, 2025, 11:36 AM EDT - 3 months ago

European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma

Jul 22, 2025, 8:30 AM EDT - 3 months ago

Halozyme to Report Second Quarter 2025 Financial and Operating Results

Jul 14, 2025, 4:33 PM EDT - 3 months ago

Halozyme: Is Robust Growth Masking A Long-Term Value Trap? (Rating Downgrade)

Jun 30, 2025, 4:05 PM EDT - 4 months ago

Halozyme Therapeutics Added to Russell 1000® Index

Jun 20, 2025, 1:15 PM EDT - 4 months ago

Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

May 28, 2025, 8:30 AM EDT - 5 months ago

Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications

May 12, 2025, 10:44 AM EDT - 5 months ago

Halozyme Therapeutics: Q1 Earnings Reveal A Bigger And Deeper Moat

May 6, 2025, 7:15 PM EDT - 6 months ago

Halozyme Therapeutics, Inc. (HALO) Q1 2025 Earnings Call Transcript

May 6, 2025, 4:01 PM EDT - 6 months ago

HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS

May 5, 2025, 5:15 PM EDT - 6 months ago

Halozyme to Participate in the BofA Securities 2025 Healthcare Conference

May 1, 2025, 9:06 AM EDT - 6 months ago

Halozyme Therapeutics: Still Undervalued Ahead Of Earnings

Apr 28, 2025, 8:30 AM EDT - 6 months ago

Halozyme to Report First Quarter 2025 Financial and Operating Results

Apr 28, 2025, 7:30 AM EDT - 6 months ago

Halozyme Announces argenx Received Positive CHMP Opinion for VYVGART® (efgartigimod alfa) Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Apr 24, 2025, 8:30 AM EDT - 6 months ago

Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation

Apr 10, 2025, 6:15 PM EDT - 7 months ago

Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy

Apr 9, 2025, 8:45 AM EDT - 7 months ago

European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility

Apr 7, 2025, 9:29 AM EDT - 7 months ago

European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Mar 31, 2025, 8:30 AM EDT - 7 months ago

Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor Indications

Mar 21, 2025, 7:35 AM EDT - 7 months ago

Halozyme Joins the $1 Billion Club

Feb 26, 2025, 8:30 AM EST - 8 months ago

Halozyme to Participate in the TD Cowen 45th Annual Healthcare Conference

Feb 18, 2025, 7:55 PM EST - 8 months ago

Halozyme Therapeutics, Inc. (HALO) Q4 2024 Earnings Call Transcript

Feb 18, 2025, 4:01 PM EST - 8 months ago

HALOZYME REPORTS FULL YEAR 2024 RECORD REVENUE OF $1.015 BILLION AND EXCEEDS ITS FINANCIAL GUIDANCE FOR ROYALTY REVENUE, ADJUSTED EBITDA AND NON-GAAP DILUTED EPS

Feb 4, 2025, 8:30 AM EST - 9 months ago

Halozyme to Report Fourth Quarter and Full Year 2024 Financial and Operating Results

Feb 3, 2025, 7:30 AM EST - 9 months ago

CHMP Issues Positive Opinion for Subcutaneous RYBREVANT®(amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Jan 8, 2025, 7:00 AM EST - 10 months ago

Halozyme Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial Guidance

Jan 6, 2025, 8:30 AM EST - 10 months ago

Halozyme to Host Investor Conference Call to Provide Updated 2025 Financial Guidance

Jan 3, 2025, 3:42 PM EST - 10 months ago

Halozyme: 'Accidental' Business Model Has Exciting Upside Opportunities In 2025

Dec 31, 2024, 2:41 AM EST - 10 months ago

Halozyme: Recent Approvals Alter My Appetite

Dec 30, 2024, 7:00 AM EST - 10 months ago

Halozyme Announces Takeda Received Regulatory Approval for HYQVIA® 10% Subcutaneous Injection Set with ENHANZE® in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

Dec 30, 2024, 6:45 AM EST - 10 months ago

Halozyme Announces argenx's VYDURA with ENHANZE® was Granted Regulatory Approval in Japan for Chronic Inflammatory Demyelinating Polyneuropathy

Dec 30, 2024, 6:30 AM EST - 10 months ago

Halozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig™ with ENHANZE® for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo® (nivolumab) Indications

Nov 27, 2024, 8:30 AM EST - 11 months ago

Halozyme to Present at Upcoming Investor Conferences

Nov 22, 2024, 8:55 AM EST - 1 year ago

Halozyme withdraws $2.1 bln buyout offer for Evotec

EVO

Nov 22, 2024, 8:35 AM EST - 1 year ago

Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions

EVO

Nov 18, 2024, 4:00 PM EST - 1 year ago

Halozyme CEO: Evotec Is Poised for Growth

EVO

Nov 18, 2024, 7:49 AM EST - 1 year ago

Halozyme says €2 billion takeover of Evotech would create leader in drug discovery

Nov 18, 2024, 7:00 AM EST - 1 year ago

Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec

EVO

Nov 15, 2024, 12:56 PM EST - 1 year ago

Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion

EVO

Sean29md Oct. 24 at 5:16 PM

1 · Reply

ZacksResearch Oct. 23 at 4:06 PM

0 · Reply

ZacksResearch Oct. 23 at 3:06 PM

0 · Reply

Sean29md Oct. 22 at 3:08 PM

0 · Reply

Sean29md Oct. 21 at 4:23 PM

0 · Reply

JarvisFlow Oct. 20 at 3:35 PM

Morgan Stanley has updated their rating for Halozyme Therapeutics ( $HALO ) to Overweight with a price target of 79.

1 · Reply

Sean29md Oct. 20 at 3:23 PM

$HALO Many thanks to Morgan Stanley for the opportunity to load up more one week ahead of earnings.

1 · Reply

Sean29md Oct. 20 at 2:33 PM

$HALO Many thanks to Morgan Stanley for the opportunity to load up more one week ahead of earnings.

0 · Reply

NoobyDoo Oct. 17 at 4:32 PM

$HALO Something big this way comes…Gilead partnership announcement soon? 🤔 I like our chances $HALO

1 · Reply

MoneyGroupLLC Oct. 17 at 3:39 PM

Enter: $HALO NOV 21 2025 $70 CALLS Buy in Price: $2.50 - $2.65 Take Profit: $3.55 Stop Bleeding: $2.20 ROI Potential: 42% Exit Within: 3 Weeks https://moneygroup.us/alerts

0 · Reply

ZacksResearch Oct. 16 at 6:38 PM

$HALO up nearly 40% YTD — is it time to chase or chill? 🧐 The rally’s powered by surging ENHANZE royalties, and the Elektrofi deal adds a solid long-term diversification angle. Full strategy breakdown here 👉 https://www.zacks.com/stock/news/2770532/halozyme-rallies-almost-40-ytd-how-should-you-play-the-stock?cid=sm-stocktwits-2-2770532-teaser-16493&ADID=SYND_STOCKTWITS_TWEET_2_2770532_TEASER_16493

0 · Reply

ZacksResearch Oct. 16 at 5:38 PM

$HALO soaring 38.8% as of now — but is it time to hold? 🤔 💊 Strong royalty revenue growth, up 52.3% year over year in the first half of 2025 💼 New Elektrofi deal set to diversify and support long-term growth 📈 2025 revenue guidance up 26-33% over 2024 Discover why HALO might still be a hold amid its rally 👉 https://www.zacks.com/stock/news/2770532/halozyme-rallies-almost-40-ytd-how-should-you-play-the-stock?cid=sm-stocktwits-2-2770532-body-16481&ADID=SYND_STOCKTWITS_TWEET_2_2770532_BODY_16481

0 · Reply

JarvisFlow Oct. 15 at 10:32 AM

HC Wainwright & Co. updates rating for Halozyme Therapeutics ( $HALO ) to Buy, target set at 90.

0 · Reply

Sean29md Oct. 15 at 1:12 AM

$HALO Helen today: "Now that drug developers have a better grasp of the IRA’s impact, Halozyme has seen a ramp-up of deal discussions over the last 12 months, and Torley said she’s “very pleased" with the ongoing conversations. “We are going to sign and announce a deal this year, and we’re very excited about that,” the Halozyme CEO said.”

0 · Reply

Sean29md Oct. 15 at 1:06 AM

$HALO Helen's interview with Fierce Pharma https://www.fiercepharma.com/pharma/halozyme-ceo-targets-ma-and-new-deals-ira-uncertainty-pharma-subsides

0 · Reply

notreload_ai Oct. 14 at 6:36 PM

Leerink upgrades $HALO to Market Perform after company reveals only 20% of ENHANZE sales come from Medicare Part B, significantly less than feared. Price target remains $70. https://notreload.xyz/halozyme-upgraded-medicare-fears-ease/

0 · Reply

JarvisFlow Oct. 14 at 6:22 PM

Leerink Partners updates rating for Halozyme Therapeutics ( $HALO ) to Market Perform, target set at 70.

0 · Reply

Sean29md Oct. 14 at 1:47 PM

$HALO Johnson & Johnson’s Darzalex (daratumumab) sales for Q3 2025 exceeded market estimates. Worldwide net sales reached $3.672 billion, surpassing the consensus analyst forecast

0 · Reply

Sean29md Oct. 14 at 1:14 PM

$HALO Halozyme’s position statement on CMS Final IPAY 2028 Guidance. https://www.sec.gov/Archives/edgar/data/1159036/000115903625000039/halozymestatementoncmsfi.htm

0 · Reply

Sean29md Oct. 13 at 3:07 AM

$HALO Forecast of halozyme price action with Gilead Enhanze partnership https://chatgpt.com/s/t_68ec65b25c088191b3e2c72a99d24886 https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2025188901

0 · Reply

Sean29md Oct. 11 at 6:53 PM

$HALO halozyme compared to S&P 500

0 · Reply

Sean29md Oct. 11 at 4:14 PM

$HALO 2025 PE ratio estimate is now with a 10 handle (10.9, see link below). I think this is the lowest current full calendar year estimated PE halozyme has ever traded at since it became profitable 5 years ago. The 2024 PE ratio is 16. This means that for halo to maintain the same PE ratio in 2025 as 2024, by the end of 4th quarter 2025 (let's say Feb 2026 when halozyme releases the 4th quarter earnings) PE has to go from 10 to 16. That is a 60% appreciation in shareprice and this would not even factor in the increase in earnings quarter over quarter. In other words, even with the same valuations and assuming zero increase in earnings (which we know will not be the case), halozyme is due for massive run up. 60% increase, would take it to $102. And the amazing thing about that share price is that it will represent a PE of only 16; still be a bargain for a +70% profit margin company with +25% EPS CAGR. https://www.nasdaq.com/market-activity/stocks/halo/price-earnings-peg-ratios

0 · Reply

Market Cap	7.74B
Revenue (ttm)	1.02B
Net Income (ttm)	444.09M
EPS (ttm)	N/A
PE Ratio	13.76
Forward PE	11.41
Profit Margin	43.74%
Debt to Equity Ratio	4.54

Volume	994,200
Avg Vol	2,059,548
Day's Range	N/A - N/A
Shares Out	116.97M
Stochastic %K	42%
Beta	1.16
Analysts	Sell
Price Target	$75.56